Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BI 894416 Alone vs With Itraconazole in Healthy Men
NCT03722173Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 894416 in asthma, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 72 hours and Maximum Measured Concentration of BI 894416 in Plasma at 72 hours. Started Nov 2018; status: completed.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03722173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722173.